Ultragenyx Pharmaceutical (RARE) EBIAT (2016 - 2025)
Historic EBIAT for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$180.4 million.
- Ultragenyx Pharmaceutical's EBIAT fell 3512.46% to -$180.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$579.8 million, marking a year-over-year decrease of 372.83%. This contributed to the annual value of -$569.2 million for FY2024, which is 617.43% up from last year.
- Per Ultragenyx Pharmaceutical's latest filing, its EBIAT stood at -$180.4 million for Q3 2025, which was down 3512.46% from -$115.0 million recorded in Q2 2025.
- Over the past 5 years, Ultragenyx Pharmaceutical's EBIAT peaked at -$73.0 million during Q3 2021, and registered a low of -$245.1 million during Q3 2022.
- Its 5-year average for EBIAT is -$146.5 million, with a median of -$151.1 million in 2025.
- As far as peak fluctuations go, Ultragenyx Pharmaceutical's EBIAT crashed by 58361.84% in 2021, and later soared by 3486.53% in 2023.
- Ultragenyx Pharmaceutical's EBIAT (Quarter) stood at -$122.5 million in 2021, then decreased by 23.99% to -$151.8 million in 2022, then increased by 18.86% to -$123.2 million in 2023, then dropped by 8.28% to -$133.4 million in 2024, then crashed by 35.26% to -$180.4 million in 2025.
- Its EBIAT stands at -$180.4 million for Q3 2025, versus -$115.0 million for Q2 2025 and -$151.1 million for Q1 2025.